Current Intrahepatic Cholangiocarcinoma News and Events

Current Intrahepatic Cholangiocarcinoma News and Events, Intrahepatic Cholangiocarcinoma News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 4 | 133 Results
Lab-grown 'mini-bile ducts' used to repair human livers in regenerative medicine first
Scientists at the University of Cambridge have used a technique to grow bile duct organoids - often referred to as 'mini-organs' - in the lab and shown that these can be used to repair damaged human livers. This is the first time that the technique has been used on human organs. (2021-02-18)

Organoids grown from bile duct cells repair human livers; may aid liver transplant processes
Organoids grown from bile duct epithelial cells can be used to repair damaged bile ducts in transplanted human livers, researchers report. (2021-02-18)

Combining PD-1inhibitor with VEGF inhibitor in chemotherapy of cholangiocarcinoma patient
Cholangiocarcinoma is the second most frequent liver cancer. Many patients miss the opportunity of having a surgery performed on them and its control has always been considered difficult. Here, doctors from The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China, present a case of stage 4 cholangiocarcinoma. (2021-02-02)

Green med diet cuts non-alcoholic fatty liver disease by half - Ben-Gurion U. study
Overall, the green MED diet produced dramatic reductions in fatty liver. NAFLD prevalence dropped from 62% at baseline to 31.5% in the green Mediterranean group, down to 47.9% in the Mediterranean group and 54.8% in the healthy dietary regimen group. Addressing this common liver disease by targeted lifestyle intervention might promote a more effective nutritional strategy. This Ben-Gurion University of the Negev clinical trial demonstrates an effective nutritional tool for NAFLD beyond weight loss (2021-01-18)

Discovery of a new approach to inhibiting a highly treatment-refractory liver cancer
Blocking placental growth factor (PlGF), a member of the vascular endothelial growth factor family, inhibits the progression of intrahepatic cholangiocarcinoma (ICC) and enhances the efficacy of chemotherapy in mouse models. This novel approach to targeting the connective tissue microenvironment of ICC, a rare but notoriously treatment-resistant form of liver cancer, could pave the way for combination therapies, including chemotherapy and immune checkpoint blockade. (2021-01-12)

Oncotarget: Characterization of porcine hepatocellular carcinoma for liver cancer
Volume 11, Issue 28 of Oncotarget features ''Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation'' by Gaba et, al. which reported that reliable development of Oncopig HCC cell lines was demonstrated through hepatocyte isolation and Cre recombinase exposure across 15 Oncopigs. (2020-10-10)

Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations
In a Phase II trial led by MD Anderson researchers, a combination targeted therapy acheived a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients. (2020-08-17)

Scientists discover a new mechanism controlling liver cancer development
CNIC scientists have designed an animal model to study the development of liver cancer caused by bile acids. This study, published in PNAS, shows that the PPAR╬▒ protein, when blocked, dramatically reduces the impact and progression of cholangiocarcinoma (2020-07-01)

Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center. (2020-05-29)

Changes in surface sugarlike molecules help cancer metastasize
Changes in a specific type of sugarlike molecule, or glycan, on the surface of cancer cells help them to spread into other tissues, according to researchers at UC Davis. (2020-03-24)

Bile duct cancer treatment potential boost from tailored medication -- study
Treatment of patients suffering from bile duct cancer could be improved by tailoring medication to the levels of a key protein in people with the disease, according to new research. (2020-02-14)

Eternygen presents data demonstrating INDY inhibition as novel therapeutic option in NASH
Study to be presented at 3rd Global NASH Congress in London, U.K., February 10, 11. Data shows, for the first time, that INDY inhibition attenuates diet-induced NASH and mINDY inhibitors may be a novel therapeutic option. In a murine NASH model, a small molecule INDY inhibitor reduced transaminases, hepatic injury, steatosis and inflammation, and improved glucose metabolism and body composition compared to vehicle-treated mice (2020-02-10)

Study suggests new strategy for treating advanced, progressing bile duct cancer
A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) shows how resistance to a promising targeted drug develops in patients with a rare, lethal cancer of the bile ducts called cholangiocarcinoma. (2020-01-14)

Bile duct biomarker? Protein found to pinpoint patients with a lethal cancer
Patients with intrahepatic cholangiocarcinoma (ICC), a form of bile duct cancer, have a poor prognosis. Researchers at Tokyo Medical and Dental University (TMDU) identified a protein called ARID1A that contributes to poor outcomes in ICC. Loss of ARID1A enhances the malignancy of ICC tumor cells and can predict worse survival outcomes. The findings could eventually form the basis of a prognostic biomarker for ICC and new treatment options for ARID1A-negative patients. (2019-12-05)

Impaired liver function during pregnancy may increase risk of childhood obesity
Impaired liver function during pregnancy may alter gut bacteria composition and increase the risk of obesity in children, according to results presented at The Society for Endocrinology Annual Conference. In a rodent of model of the most common liver disease in pregnancy, the composition of gut bacteria in offspring was altered and liver function impaired, particularly when they were fed a Western-style, high-fat diet. (2019-11-10)

Deaths from liver cancer have tripled in past 20 years in England
More people are being diagnosed with and dying from liver cancer in England than ever before, according to new research to be presented at the 2019 NCRI Cancer Conference. In 20 years, from 1997 to 2016, incidence and deaths from the most common form of the disease, hepatocellular carcinoma, have tripled and it is most common among the most deprived members of society. (2019-10-31)

First targeted therapy for cholangiocarcinoma shows clinical benefit in phase III trial
New data have shown for the first time that targeted therapy can improve the outcome of patients diagnosed with advanced cholangiocarcinoma. Cholangiocarcinoma is a subtype of bile duct cancer with aggressive behaviour and poor prognosis. Despite the low incidence, most patients die from the disease and therefore new effective therapies are urgently needed. (2019-09-30)

Obesity pandemic shifting cancer to younger people
A new study looking at incidence of disease data nationwide from 2000 to 2016 found a shift in obesity-associated cancers (OACs) to younger individuals. Typically, these cancers are diagnosed at higher rates among people older than 65. The most notable findings pertain to increases in these OACs among non-Hispanic Black and Hispanic women and men for whom certain cancers increased by 200-400%. (2019-09-03)

Treatment for liver disorder in pregnancy ineffective, finds new study
Research led by King's College London has found that the currently recommended treatment for a common pregnancy liver disorder that can result in preterm birth and stillbirth, is ineffective and should be reconsidered. (2019-08-01)

NCI-MATCH trial finds the combination of dabrafenib and trametinib effective
Findings from NCI-MATCH Arm H, orally presented on Monday, June 3rd at the ASCO 2019 annual meeting in Chicago, show that in a heavily pre-treated cohort of 17 distinct tumor types -- several rare -- with BRAF mutations, the combination of dabrafenib and trametinib showed promising activity outside of currently approved FDA indications. NCI-MATCH is reporting results from its 39 treatment arms as they become available. With 11 arms reported so far, three have positive results. (2019-06-03)

New connection found between NAFLD and rare pregnancy complication
A new link has been found between a rare and serious condition that typically presents as itchy palms during pregnancy and the world's most common chronic liver disease, according to research presented at Digestive Disease Week® (DDW) 2019. Researchers found that intrahepatic cholestasis of pregnancy (ICP), a bile acid disorder in adults that affects roughly one of every 300 pregnancies, may be associated with non-alcoholic fatty liver disease (NAFLD). (2019-05-09)

Simple bile acid blood test could tell risk of stillbirth
Clinical researchers at Guy's and St Thomas' and King's College London have found a better way to measure the risk of stillbirth for women with a common liver disorder through a simple blood test. (2019-02-14)

The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease
Data indicates that high intrahepatic or circulating PCSK9 levels increase muscle and liver lipid storage, adipose energy storage and hepatic fatty acids, as well as triglycerides storage and secretion, thus contributing to the pathogenesis of NAFLD. The findings of animal and human studies, aiming to reduce PCSK9 with inhibitors point towards liver protection from NAFLD through inhibition of PCSK9 expression in the induction of degradation of hepatic HNF1a protein, insulin resistance (IR), and other mechanisms. (2019-01-01)

More protein after weight loss may reduce fatty liver disease
Increasing the amount of protein in the diet may reduce the liver's fat content and lower the risk of diabetes in people with nonalcoholic fatty liver disease (NAFLD). The study is published ahead of print in the American Journal of Physiology--Endocrinology and Metabolism. (2018-08-16)

Half of all young children with a rare inherited liver disease need a liver transplant
An international research team has today reported the first results of a study investigating the natural history of progressive familial intrahepatic cholestasis (PFIC) -- a rare genetic liver disease that predominantly affects children. Most alarmingly, the team reported that, by the age of 10 years, approximately half of the children with two different forms of PFIC had already received a liver transplant. (2018-05-10)

TGen develops quality-control test for detecting cancer in blood
There is vast potential in precision-medicine methods of both detecting and monitoring disease by looking for indications of cancer mutations in cell-free DNA (cfDNA), found floating in the blood. To help ensure the quality of these molecular biomarkers, a scientific team led by the Translational Genomics Research Institute (TGen) has devised a rapid test -- a droplet digital PCR (ddPCR) assay -- so these samples can be used to help determine the presence and progression of disease. (2018-05-09)

Sensitive new assay detects hepatitis B infection in single liver cells and serum
Chronic hepatitis B virus (HBV) can progress to cirrhosis and hepatocellular carcinoma (HCC). A study published in The Journal of Molecular Diagnostics describes a new HBV assay that offers advantages over currently used methods because it has the capability to detect closed circular DNA (cccDNA) in serum, single cells, and preserved tissue samples. This assay can be used to diagnose HCC at an earlier stage to manage treatment more effectively. (2018-04-12)

New blood test may transform the way cancer is monitored and treated
Stanford University scientists have described a new type of test that can detect genetic mutations in minute amounts of DNA released from cancer cells into the blood. The test, which is called single color digital PCR, requires only a fraction of a tube of blood and can detect as few as three mutation-bearing molecules in a single reaction. According to the report, this highly sensitive test has the potential to be personalized to recognize mutations unique to any individual cancer. (2017-08-14)

How bile duct cancer develops and how it can be prevented
What promotes the development of bile duct cancer in the liver? Are these factors different from those that are responsible for the much more common hepatocellular carcinomas? Scientists from the Heidelberg and Munich have been the first to uncover the molecular causes that selectively lead to the development of bile duct cancer in mice. The researchers also discovered that antioxidants or an inhibitor of a specific key enzyme can be used to stop this cancer-promoting process. (2017-06-12)

Drug improves survival of patients with rare cancer by almost a quarter
Patients who take capecitabine after surgery for bile duct cancer live for almost a year and a half longer than those not given the drug. (2017-05-17)

Interferon-beta producing stem cell-derived immune cell therapy on liver cancer
Induced pluripotent stem (iPS) cell-derived myeloid cells (iPS-ML) that produce the anti-tumor protein interferon-beta (IFN-beta) have been produced and analyzed by researchers from Kumamoto University, Japan. Using human iPS-ML in a mouse model, they found that the cells migrate to and deliver IFN-beta to liver tumors thereby reducing cancer proliferation and increasing survival time. (2017-03-28)

Mass. General team identifies mechanisms behind resistance to FGFR inhibitor drug
Investigators at the Massachusetts General Hospital Cancer Center have identified the first genetic mechanisms conferring acquired resistance to a promising group of targeted cancer drugs. (2017-03-23)

Researchers map clonorchiasis risk across China
Clonorchiasis, a neglected tropical disease usually acquired by eating undercooked freshwater fish, affects an estimated 15 million people around the globe. More than 85 percent of cases are concentrated in China. Now, researchers have produced high-resolution risk maps for clonorchiasis in China. Their results, published in PLOS Neglected Tropical Diseases, identified provinces with the highest risk and important predictors for clonorchiasis. Moreover, the risk of the disease has been profiled for areas without survey data. (2017-03-07)

Recent investigations on human group II pyridoxal 5'-phosphate decarboxylases
The aim of the present article is to compare the structural features of a particular group of pyridoxal 5'-phosphate-dependent decarboxylases, namely the group II ?-decarboxylases. These enzymes are: aromatic amino acid, cysteine sulfinic acid, glutamate and histidine decarboxylases. They are involved in the synthesis of dopamine/serotonin, hypotaurine, ?-aminobutyric acid and histamine, respectively, molecules known to play essential biological roles. (2017-02-28)

Discovery of a new gene critical in the development of lung and pancreatic cancers
Researchers at the Center for Applied Medical Research (CIMA) of the University of Navarra (Spain) have identified a critical gene, FOSL1, in the development of lung and pancreatic cancer. The work, published in Nature Communications, shows that the inhibition of FOSL1 brings about a great reduction in the size of the tumors in the lungs and pancreas. Thus, the results present this gene as a new molecular target to which new drugs should be directed. (2017-02-21)

A drug that inhibits the Notch signalling process is active in a range of advanced cancers
A new anti-cancer drug that inhibits a key cell signalling process involved in many different cancers has shown that it is capable of stopping the progression of cancer and shrinking tumors; importantly, in rare, less well-studied cancers such as adenoid cystic carcinoma. Dr. Christophe Massard told the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics that the drug LY3039478 was successful in inhibiting the Notch signalling pathway in patients with alterations in the Notch protein. (2016-12-01)

Bile duct cancer study sheds light on triggers that cause disease
Scientists at the University of Edinburgh have identified a molecule that drives the development of bile duct cancer. The research in mice sheds new light on what triggers the disease and how the illness progresses. (2016-10-10)

Moderate and vigorous exercise have comparable effects on nonalcoholic fatty liver disease
A brisk walk is just as good as a jog when it comes to fighting nonalcoholic fatty liver disease, study involving Tulane researchers finds. (2016-07-05)

Aspirin may help prevent bile duct cancer
Regular use of aspirin was linked with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, in a recent study. (2016-04-26)

Aspirin use may help prevent bile duct cancer, Mayo-led study finds
A team of current and former Mayo Clinic researchers has discovered that aspirin use is associated with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma. The results are published in Hepatology. (2016-04-19)

Page 1 of 4 | 133 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to